Ingalls & Snyder LLC raised its position in Concert Pharmaceuticals Inc (NASDAQ:CNCE) by 8.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,314,562 shares of the biotechnology company’s stock after buying an additional 105,500 shares during the quarter. Concert Pharmaceuticals makes up approximately 1.6% of Ingalls & Snyder LLC’s portfolio, making the stock its 11th biggest position. Ingalls & Snyder LLC owned approximately 0.06% of Concert Pharmaceuticals worth $34,008,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company raised its stake in shares of Concert Pharmaceuticals by 1.9% during the second quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock worth $210,000 after purchasing an additional 287 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Concert Pharmaceuticals by 8.0% during the second quarter. Rhumbline Advisers now owns 20,253 shares of the biotechnology company’s stock worth $283,000 after purchasing an additional 1,500 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Concert Pharmaceuticals by 1.5% during the second quarter. Bank of New York Mellon Corp now owns 125,996 shares of the biotechnology company’s stock worth $1,757,000 after purchasing an additional 1,852 shares during the last quarter. Teachers Advisors LLC raised its stake in shares of Concert Pharmaceuticals by 11.1% during the second quarter. Teachers Advisors LLC now owns 34,373 shares of the biotechnology company’s stock worth $480,000 after purchasing an additional 3,446 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of Concert Pharmaceuticals by 3.0% during the third quarter. Principal Financial Group Inc. now owns 118,600 shares of the biotechnology company’s stock worth $1,749,000 after purchasing an additional 3,500 shares during the last quarter. Institutional investors and hedge funds own 65.29% of the company’s stock.

In related news, Director Ronald W. Barrett sold 14,156 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $24.70, for a total transaction of $349,653.20. Following the transaction, the director now owns 3,539 shares of the company’s stock, valued at $87,413.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Value Fund L. P. Biotechnology sold 1,282,856 shares of the company’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $26.65, for a total value of $34,188,112.40. The disclosure for this sale can be found here. Insiders have sold 1,328,248 shares of company stock worth $35,135,623 in the last ninety days. 10.10% of the stock is currently owned by corporate insiders.

Several research firms have recently commented on CNCE. HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of Concert Pharmaceuticals in a research note on Friday, October 20th. Zacks Investment Research cut Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, September 22nd. Stifel Nicolaus restated a “buy” rating and set a $30.00 price target on shares of Concert Pharmaceuticals in a research note on Sunday, October 22nd. Mizuho began coverage on Concert Pharmaceuticals in a research note on Thursday, October 26th. They set a “buy” rating and a $23.00 price target for the company. Finally, TheStreet upgraded Concert Pharmaceuticals from a “d” rating to a “c+” rating in a research note on Wednesday, November 29th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $24.33.

Shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) traded down $0.10 during mid-day trading on Friday, reaching $19.61. The company had a trading volume of 519,161 shares, compared to its average volume of 726,546. Concert Pharmaceuticals Inc has a 52-week low of $8.61 and a 52-week high of $30.71. The firm has a market capitalization of $446.57, a price-to-earnings ratio of 5.23 and a beta of 1.67.

Concert Pharmaceuticals (NASDAQ:CNCE) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.16). Concert Pharmaceuticals had a negative return on equity of 51.48% and a net margin of 62.31%. research analysts expect that Concert Pharmaceuticals Inc will post 4.1 EPS for the current year.

WARNING: “Ingalls & Snyder LLC Raises Holdings in Concert Pharmaceuticals Inc (CNCE)” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.watchlistnews.com/ingalls-snyder-llc-raises-holdings-in-concert-pharmaceuticals-inc-cnce/1814428.html.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Want to see what other hedge funds are holding CNCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Concert Pharmaceuticals Inc (NASDAQ:CNCE).

Institutional Ownership by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.